Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies.

Ross JS, Ali SM, Wang K, Palmer G, Yelensky R, Lipson D, Miller VA, Zajchowski D, Shawver LK, Stephens PJ.

Gynecol Oncol. 2013 Sep;130(3):554-9. doi: 10.1016/j.ygyno.2013.06.019. Epub 2013 Jun 20.

2.

Treatment-related protein biomarker expression differs between primary and recurrent ovarian carcinomas.

Zajchowski DA, Karlan BY, Shawver LK.

Mol Cancer Ther. 2012 Feb;11(2):492-502. doi: 10.1158/1535-7163.MCT-11-0746. Epub 2011 Dec 27.

3.
4.

Smart drugs: tyrosine kinase inhibitors in cancer therapy.

Shawver LK, Slamon D, Ullrich A.

Cancer Cell. 2002 Mar;1(2):117-23. Review.

5.

Application of LC/MS/MS in the quantitation of SU101 and SU0020 uptake by 3T3/PDGFr cells.

Zhang Q, Pang WL, Chen H, Cherrington J, Lipson K, Antonian L, Shawver LK.

J Pharm Biomed Anal. 2002 May 15;28(3-4):701-9.

PMID:
12008150
6.

Pharmacokinetics and interspecies scaling of a novel VEGF receptor inhibitor, SU5416.

Sukbuntherng J, Cropp G, Hannah A, Wagner GS, Shawver LK, Antonian L.

J Pharm Pharmacol. 2001 Dec;53(12):1629-36.

PMID:
11804393
7.

The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function.

Mendel DB, Schreck RE, West DC, Li G, Strawn LM, Tanciongco SS, Vasile S, Shawver LK, Cherrington JM.

Clin Cancer Res. 2000 Dec;6(12):4848-58.

8.

Biotransformation of the anti-angiogenic compound SU5416.

Antonian L, Zhang H, Yang C, Wagner G, Shawver LK, Shet M, Ogilvie B, Madan A, Parkinson A.

Drug Metab Dispos. 2000 Dec;28(12):1505-12.

PMID:
11095590
9.

SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.

Laird AD, Vajkoczy P, Shawver LK, Thurnher A, Liang C, Mohammadi M, Schlessinger J, Ullrich A, Hubbard SR, Blake RA, Fong TA, Strawn LM, Sun L, Tang C, Hawtin R, Tang F, Shenoy N, Hirth KP, McMahon G, Cherrington.

Cancer Res. 2000 Aug 1;60(15):4152-60.

10.

Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice.

Lenferink AE, Simpson JF, Shawver LK, Coffey RJ, Forbes JT, Arteaga CL.

Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9609-14.

11.

Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts.

Strawn LM, Kabbinavar F, Schwartz DP, Mann E, Shawver LK, Slamon DJ, Cherrington JM.

Clin Cancer Res. 2000 Jul;6(7):2931-40.

12.

Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent.

Mendel DB, Laird AD, Smolich BD, Blake RA, Liang C, Hannah AL, Shaheen RM, Ellis LM, Weitman S, Shawver LK, Cherrington JM.

Anticancer Drug Des. 2000 Feb;15(1):29-41. Review.

PMID:
10888034
13.

New paradigms for the treatment of cancer: the role of anti-angiogenesis agents.

Cherrington JM, Strawn LM, Shawver LK.

Adv Cancer Res. 2000;79:1-38. Review.

PMID:
10818676
14.

Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity.

Busse D, Doughty RS, Ramsey TT, Russell WE, Price JO, Flanagan WM, Shawver LK, Arteaga CL.

J Biol Chem. 2000 Mar 10;275(10):6987-95.

15.

Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases.

Sun L, Tran N, Liang C, Tang F, Rice A, Schreck R, Waltz K, Shawver LK, McMahon G, Tang C.

J Med Chem. 1999 Dec 16;42(25):5120-30.

PMID:
10602697
16.
17.

SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.

Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Ullrich A, Hirth KP, McMahon G.

Cancer Res. 1999 Jan 1;59(1):99-106.

18.
19.

Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide.

Shawver LK, Schwartz DP, Mann E, Chen H, Tsai J, Chu L, Taylorson L, Longhi M, Meredith S, Germain L, Jacobs JS, Tang C, Ullrich A, Berens ME, Hersh E, McMahon G, Hirth KP, Powell TJ.

Clin Cancer Res. 1997 Jul;3(7):1167-77.

20.

Flk-1 as a target for tumor growth inhibition.

Strawn LM, McMahon G, App H, Schreck R, Kuchler WR, Longhi MP, Hui TH, Tang C, Levitzki A, Gazit A, Chen I, Keri G, Orfi L, Risau W, Flamme I, Ullrich A, Hirth KP, Shawver LK.

Cancer Res. 1996 Aug 1;56(15):3540-5.

21.

Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo.

Millauer B, Longhi MP, Plate KH, Shawver LK, Risau W, Ullrich A, Strawn LM.

Cancer Res. 1996 Apr 1;56(7):1615-20.

22.

Membrane bound receptor tyrosine kinases and chemical carcinogenesis.

Shawver LK, Strawn LM, Ullrich A.

Mutat Res. 1995 Dec;333(1-2):23-8. Review. No abstract available.

PMID:
8538631
23.

Construction of a chimeric antibody with therapeutic potential for cancers which overexpress c-erbB-2.

Liu HL, Parkes DL, Langton BC, Xuan JA, Longhi M, Elliger SS, Chao LA, McGrogan MP, Brandis JW, Shawver LK.

Biochem Biophys Res Commun. 1995 Jun 26;211(3):792-803.

PMID:
7598708
24.

A tumor-derived protein which provides T-cell costimulation through accessory cell activation.

Powell TJ, Schreck R, McCall M, Hui T, Rice A, App H, Azam M, Ullrich A, Shawver LK.

J Immunother Emphasis Tumor Immunol. 1995 May;17(4):209-21.

PMID:
7582257
25.

Inhibition of glioma cell growth by a truncated platelet-derived growth factor-beta receptor.

Strawn LM, Mann E, Elliger SS, Chu LM, Germain LL, Niederfellner G, Ullrich A, Shawver LK.

J Biol Chem. 1994 Aug 19;269(33):21215-22.

26.

p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair.

Arteaga CL, Winnier AR, Poirier MC, Lopez-Larraza DM, Shawver LK, Hurd SD, Stewart SJ.

Cancer Res. 1994 Jul 15;54(14):3758-65.

27.
28.

Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant.

Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A.

Nature. 1994 Feb 10;367(6463):576-9.

PMID:
8107827
29.

A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines.

Hancock MC, Langton BC, Chan T, Toy P, Monahan JJ, Mischak RP, Shawver LK.

Cancer Res. 1991 Sep 1;51(17):4575-80.

30.
32.

Characterization of pp64, a nuclear phosphoprotein induced by platelet-derived growth factor.

Shawver LK, Behrens CB, Deuel TF.

Biochem Biophys Res Commun. 1989 Jun 30;161(3):1118-25.

PMID:
2742578
33.

Platelet-derived growth factor induces phosphorylation of a 64-kDa nuclear protein.

Shawver LK, Pierce GF, Kawahara RS, Deuel TF.

J Biol Chem. 1989 Jan 15;264(2):1046-50.

34.

Identification and purification of PDGF/sis-like proteins from nuclei of simian sarcoma virus-transformed fibroblasts.

Pierce GF, Shawver LK, Milner PG, Yeh HJ, Thomason A, Deuel TF.

Oncogene Res. 1988 Feb;2(3):235-44.

PMID:
2835737
35.

Down-modulation of EGF receptors in cells transformed by the src oncogene.

Wasilenko WJ, Shawver LK, Weber MJ.

J Cell Physiol. 1987 Jun;131(3):450-7.

PMID:
3036890
36.
37.

Immunoquantitation of cytochrome b5 and methylcholanthrene-induced cytochromes P-450.

Shires TK, Krieter PA, Shawver LK, Seidel SL.

Fed Proc. 1987 Jun;46(8):2567-74. Review.

PMID:
2439385
38.

Platelet-derived growth factor/sis in normal and neoplastic cell growth.

Deuel TF, Pierce GF, Yeh HJ, Shawver LK, Milner PG, Kimura A.

J Cell Physiol Suppl. 1987;Suppl 5:95-9. Review.

PMID:
2824537
39.

Detection of phenobarbital-induced cytochrome P-450 in rat hepatic microsomes using an enzyme-linked immunosorbent assay.

Seidel SL, Shawver LK, Shires TK.

Arch Biochem Biophys. 1984 Mar;229(2):519-31.

PMID:
6703710

Supplemental Content

Loading ...
Support Center